Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Multiple Primary Lung Cancer × camrelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 8 Nasopharyngeal Carcinoma 7 Triple Negative Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Breast Neoplasms 5 Uterine Cervical Neoplasms 4 Pancreatic Neoplasms 4 Colorectal Neoplasms 4 Stomach Neoplasms 3 Liver Neoplasms 3 Esophageal Neoplasms 3 Neoplasm Metastasis 2 Gestational Trophoblastic Disease 2 Carcinoma, Non-Small-Cell Lung 2 Adrenocortical Carcinoma 2 Unresectable Gallbladder Cancer 1 Sarcoma 1 Salivary Gland Neoplasms 1 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Osteosarcoma 1 Non Squamous Non Small Cell Lung Cancer 1 Nasopharyngeal Neoplasms 1 Multiple Primary Lung Cancer 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Locally Advanced or Metastatic Solid Tumors 1 Locally Advanced Rectal Cancer 1 Liver Diseases 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05053802 2021-09-23

MAGIC

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Recruiting

Multiple Primary Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡